Daily Sabah logo

Politics
Diplomacy Legislation War On Terror EU Affairs Elections News Analysis
TÜRKİYE
Istanbul Education Investigations Minorities Expat Corner Diaspora
World
Mid-East Europe Americas Asia Pacific Africa Syrian Crisis Islamophobia
Business
Automotive Economy Energy Finance Tourism Tech Defense Transportation News Analysis
Lifestyle
Health Environment Travel Food Fashion Science Religion History Feature Expat Corner
Arts
Cinema Music Events Portrait Reviews Performing Arts
Sports
Football Basketball Motorsports Tennis
Opinion
Columns Op-Ed Reader's Corner Editorial
PHOTO GALLERY
JOBS ABOUT US RSS PRIVACY CONTACT US
© Turkuvaz Haberleşme ve Yayıncılık 2023

Daily Sabah logo

عربي
  • Politics
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • Elections
    • News Analysis
  • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Expat Corner
    • Diaspora
  • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • Islamophobia
  • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
  • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
  • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Reviews
    • Performing Arts
  • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
  • Gallery
  • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
  • TV

US pharmaceutical firm invests $35M in Istanbul facilities

by Safure Cantürk

ANKARA Apr 03, 2018 - 12:00 am GMT+3
by Safure Cantürk Apr 03, 2018 12:00 am

The U.S. pharmaceutical pioneer Amgen invested $35 million in biotech medicine in Istanbul. Amgen Global Research and Development Director Thomas Felix said Turkey's expansion in pharmaceuticals is very important.

"If high value-added products are produced, Turkey will have a strategic importance for the region," Felix said.

The increase experienced in the domestic industry with the incentives issued by the government in a support program, which included the pharmaceutical industry among primary strategic products, world giants turned their eyes to Turkey.

Listed among the top 500 companies by Fortune magazine in 2016 with a turnover of $22.5 billion, Amgen purchased Mustafa Nevzat, Turkey's largest pharmaceutical company, in 2012 for $700 million.

Amgen made the largest investment in all areas at once in Turkey. With that it brought biotechnological and biosimilar production technology to Turkey. Amgen, which made an additional investment of $35 million in biotechnology in Istanbul facilities last year, chose Turkey as a hub in the region.

Felix stated that the global health sector is moving toward biotechnology.

"It is also very important for Turkey to be in an effort to become aware of it," he said. "When we look at the future of Turkey's pharmaceutical sector, we foresee that the actual need is to produce innovative and high value-added products."

He stressed that biological drugs, which are difficult to produce in complex structures, should be produced in the highest quality, adding that quality is also of vital importance in biosimilar products.

"We are continuously making additional investments in order to achieve this as a company prioritizing quality and to bring our production facilities here to Amgen standards," he continued. "For example, in order to contribute to the production of biotechnological drugs, we have recently invested $35 million in our production facility located in Yenibosna, Istanbul and commissioned our new production lines. We do this for our patients to produce high-quality biosimilar medicines that use the latest technology."

He said biotechnological drugs, which mean the transformation of proteins obtained by genetically engineering the DNA of the live cells into drugs, have been used in the treatment of more than 800 million patients worldwide.

Noting that biotech drugs are used in the treatment of diseases such as rheumatoid arthritis, cancer, rare blood diseases, multiple sclerosis, osteoporosis and diabetes, he said biotech drugs will bring path-breaking developments to many diseases with new technologies.

  • shortlink copied
  • Last Update: Apr 03, 2018 10:52 am
    RELATED TOPICS
    fight-against-terrorism DEUTSCHE-BANK US-LIBYA-RELATIONS
    KEYWORDS
    homepage
    The Daily Sabah Newsletter
    Keep up to date with what’s happening in Turkey, it’s region and the world.
    You can unsubscribe at any time. By signing up you are agreeing to our Terms of Use and Privacy Policy. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
    No Image
    Sao Paulo hit by deadly landslides after heavy rains
    PHOTOGALLERY
    • POLITICS
    • Diplomacy
    • Legislation
    • War On Terror
    • EU Affairs
    • News Analysis
    • TÜRKİYE
    • Istanbul
    • Education
    • Investigations
    • Minorities
    • Diaspora
    • World
    • Mid-East
    • Europe
    • Americas
    • Asia Pacific
    • Africa
    • Syrian Crisis
    • İslamophobia
    • Business
    • Automotive
    • Economy
    • Energy
    • Finance
    • Tourism
    • Tech
    • Defense
    • Transportation
    • News Analysis
    • Lifestyle
    • Health
    • Environment
    • Travel
    • Food
    • Fashion
    • Science
    • Religion
    • History
    • Feature
    • Expat Corner
    • Arts
    • Cinema
    • Music
    • Events
    • Portrait
    • Performing Arts
    • Reviews
    • Sports
    • Football
    • Basketball
    • Motorsports
    • Tennis
    • Opinion
    • Columns
    • Op-Ed
    • Reader's Corner
    • Editorial
    • Photo gallery
    • Jobs
    • privacy
    • about us
    • contact us
    • RSS
    © Turkuvaz Haberleşme ve Yayıncılık 2021